Investor Relations

AmpliPhi Biosciences to Hold Business Update Conference Call on May 15

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:	U.S.	877-866-5534
	International	346-406-0930
	Passcode	20313217

Live Webcast: AmpliPhi IR Website

The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.

Replay:	U.S.	855-859-2056
	International	404-537-3406
	Passcode	20313217

The replay will be available for 48 hours starting approximately 2 hours after completion of the call.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

CONTACT:

At the Company:
AmpliPhi Biosciences
Matthew Dansey, (858) 800-4869
md@ampliphibio.com
or
Investor Relations:
LHA
Jody Cain, (310) 691-7100
jcain@lhai.com

---

https://investor.armatapharma.com/2017-05-11-AmpliPhi-Biosciences-to-Hold-Business-Update-Conference-Call-on-May-15